<DOC>
	<DOCNO>NCT00526929</DOCNO>
	<brief_summary>Multicenter , open-label , single-arm , fix dose study darbepoetin alfa subject Chronic Renal Insufficiency ( CRI ) . Subjects screen 2 week time blood drawn vital sign take . Upon enrollment , subject receive SC darbepoetin alfa administer every week 24 week . Darbepoetin alfa titrate fixed-dose step maintain hemoglobin 11.0 - 13.0 . During study , laboratory assessment complete vital sign take . Subjects enter 1-week post-treatment observation evaluation period last dose study drug .</brief_summary>
	<brief_title>Fixed Dose NESP Study Subjects With CRI</brief_title>
	<detailed_description />
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>Greater equal 18 year age CRI creatinine clearance le 40 mL/min Hemoglobin le 11.0 g/dL Serum vitamin B12 folate level low limit normal iron replete Received rHuEPO therapy last 12 week Expected initiate renal replacement therapy within 24 week recipient renal transplant Uncontrolled hypertension Seizure activity , CHF , hyperparathyroidism , major surgery , HIVpositive Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2009</verification_date>
</DOC>